SCHEMBL22022907

SCHEMBL22022907

CCOc1ccc(-c2ccc(CC(=O)Nc3cc(Cl)ccc3C(=O)O)cc2)cn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.61
▸ KMT2A Q03164 7/20 0.61
▸ KDM4E B2RXH2 3/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ ACLY P53396 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ KDM5A P29375 1/20 0.50
▸ KDM4C Q9H3R0 1/20 0.50
▸ KDM5B Q9UGL1 1/20 0.50
▸ USP2 O75604 1/20 0.47
▸ PABPC1 P11940 1/20 0.47
▸ TRPM4 Q8TD43 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ PKM P14618 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ GRIK1 P39086 1/20 0.43
▸ CSNK1D P48730 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22022875 0.91 ACLY (0.53) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL22022924 0.84 MEN1 (0.60) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL22071196 0.83 HCAR2 (0.52) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL22022916 0.83 MEN1 (0.70) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL22022914 0.82 KDM4E (0.53) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL22022864 0.80 ACLY (0.75) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL22022933 0.79 MEN1 (0.68) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL22022868 0.79 KMT2A (0.68) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL22022917 0.79 KDM4C (0.63) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2
SCHEMBL22022893 0.79 MEN1 (0.65) MEN1KMT2AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220054438-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2022-02-24 — — US disclosed
US-20220054438-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2022-02-24 — — US disclosed
EP-3890734-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES Consejo Superior de Investigaciones Científicas (CSIC) (ES) 2021-10-13 — — EP disclosed
WO-2020115019-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2020-06-11 — — WO disclosed
EP-3662908-A1 MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-06-10 — — EP disclosed
EP-3662908-A1 MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-06-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220054438-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES KCNK2, KCNT2, KCNT1 MEN1 4366/4885KMT2A 1216/4885KDM4E 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback